Tag: VIVA 2019

endovascular

Endovascular arteriovenous fistulas “key part of any dialysis programme”

Endovascular arteriovenous fistulas (endoAVF) platforms add additional fistula options for patients and physicians, argues Dheeraj Rajan (University Health Network, University of Toronto, Toronto, Canada,...

PROMISE I trial affirms potential of LimFlow system for treatment of...

Initial findings of an early feasibility trial have demonstrated that the LimFlow System does represent a safe and reproducible method of treating patients with...
paclitaxel

Full revascularisation “may not be the best solution” for CLI patients

Aiming for full revascularisation “may not be the best solution” for treating patients with critical limb ischaemia (CLI) according to Thomas Zeller (Bad Krozingen,...
Akhilesh Sista Video

New trial planned to rigorously test catheter-directed thrombolysis for submassive PE...

Clinically relevant outcomes are needed to measure catheter-directed therapy (CDT) against anticoagulation alone to treat submassive pulmonary embolism (PE) patients. Further, CDT’s ability to...

Update on regulatory landscape points to benefits of global collaboration

At the 2019 Vascular Interventional Advances (VIVA) conference in Las Vegas, USA (4–7 November), Misti Malone (US Food and Drug Administration Office for...
Daniel Clair

VIVA 2019: PROMISE I trial shows deep vein arterialisation offers hope...

Daniel Clair (Columbia, SC, USA), presented positive six-month data from the full patient cohort of the PROMISE I early feasibility study of the LimFlow...

More focus needed on best medical therapy and perfusion imaging for...

Curiously, the mortality risk for patients with critical limb ischaemia (CLI) has not changed over the last few decades, despite advances in cardiovascular medicine...

Teamwork prescribed to tackle major demographic trends in vascular disease

“Caring for vascular patients is going to take a team,” concluded Marc Bonaca (Boston, USA) at the 2019 Vascular Interventional Advances (VIVA) conference in...

CLI: “Know the patient, know the disease and know what you...

Bruce Gray (Greenville, USA) talks to Vascular News after winning the LIVE (Leader In EndoVascular Education) award at VIVA 2019 (4–7 November, Las Vegas,...

VIVA 2019: Zilver PTX shows benefits across different patient groups

At this year’s Vascular Interventional Advances (VIVA) conference (4–7 November, Las Vegas, USA), Michael D Dake presented data on Zilver PTX that supports the...

VIVA 2019: Penumbra Indigo Aspiration system IDE trial for acute PE...

Penumbra today announced that the EXTRACT-PE trial successfully met the primary endpoints, demonstrating the safety and efficacy of the Indigo Aspiration system for aspiration...

VIVA 2019: IN.PACT AV DCB shows “consistent effectiveness performance” in subgroup...

Today Medtronic shared a six-month subgroup analysis from the IN.PACT AV Access trial, which evaluated how the IN.PACT AV DCB—an investigational device not currently...

VIVA 2019: Ultrasound before angioplasty for BTK lesions may improve outcomes...

Low-frequency, high-intensity ultrasound energy delivery followed by percutaneous transluminal angioplasty (PTA) may improve clinical outcomes in below-the-knee (BTK) lesions without the need for a...

VIVA 2019: Perivascular temsirolimus could be “viable alternative” to prevent restenosis...

It was announced today that results of the TANGO low-dose cohort compared to controls are positive, both for primary and secondary endpoints. These latest...
limflow stent

VIVA 2019: LimFlow announces positive six-month data From PROMISE I US...

LimFlow SA today announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the...

VIVA 2019: ABSORB BVS achieves “excellent” long-term patency and freedom from...

Ramon Varcoe today announced positive five-year results of the ABSORB BTK trial at the 2019 Vascular Interventional Advances conference (VIVA) in Las Vegas, USA...

VIVA 2019: TOBA II BTK meets primary safety and efficacy endpoints...

It was announced today at the 2019 Vascular Interventional Advances conference (VIVA) (4–7 November, Las Vegas, USA) that, through six months, TOBA II BTK...

VIVA 2019: Temporary Spur stent system appears to be feasible and...

Today at the 2019 Vascular Interventional Advances conference (VIVA; 4–7 November, Las Vegas, USA), Thomas Zeller (Bad Krozingen, Germany) gave an update on the...

VIVA 2019: One-year freedom from clinically-driven target lesion revascularisation in MIMICS-3D...

One-year results of the MIMICS-3D study were announced today at the 2019 Vascular Interventional Advances conference (VIVA; 4–7 November, Las Vegas, USA). Freedom from...

VIVA 2019: Revolution system meets primary and safety endpoints in REVEAL...

Findings from the REVEAL study confirm a favourable safety and effectiveness profile through six months for the Revolution peripheral atherectomy system from Rex Medical....

VIVA 2019: Nexus stent graft demonstrates promising mid-term results

Positive two-year results from a prospective multicentre premarket study including 25 patients treated with the Nexus aortic arch stent graft (Endospan) were presented today...

VIVA 2019: CFA disease can be treated endovascularly with Supera stent

Two-year data confirm that common femoral artery (CFA) disease can be treated endovascularly with the Supera stent (Abbott). Results of the VMI-CFA study were...

VIVA 2019: Boston Scientific announces positive data for the Ranger DCB...

Boston Scientific today announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at the 2019...
AV access

VIVA 2019: Four-year data from the IN.PACT Global study highlight durable...

Medtronic today announced four-year data from the IN.PACT Global study, which reinforce the long-term durability and safety of the IN.PACT Admiral drug-coated balloon (DCB)...

VIVA 2019: SELUTION sirolimus DCB safe and effective through two years

The SELUTION SFA trial met its primary endpoint and demonstrated an late lumen loss of 0.19mm. Furthermore, excellent freedom from clinically driven TLR was...